The PI3K/AKT/mTOR pathway is shown to be activated in T-ALL due to PTEN inactivation, and inhibition of this pathway has demonstrated efficacy in preclinical models of T-ALL [145]. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.